Institut National de la Santé et de la Recherche Médicale;Université Paris Descartes;Assistance Publique - Hopitaux de Paris;Fondation Imagine - Institut des Maladies Génétiques
The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.